I wonder what do you think the implications are for the positive pancreatic c. results. It seems that in the CC Dr. Friedman hinted that JAK1 may be the way to go for that condition. Now, Galapagos has licensed out its JAK1 to Abbvie for two indications: RA and Crohn. Surely there must be more value in that JAK1. So teh question is: what do you think of galapagos?
thanks for your insight!